Regeneron Pharmaceuticals EVP Commercial Sells ~$984K in Common Stock Under Rule 10b5-1 Plan

Executive Summary

On November 3, 2026, Regeneron Pharmaceuticals, Inc. ($REGN) filed a Form 4 disclosing that Marion McCourt, Executive Vice President of Commercial, executed an open-market sale of common stock on October 30, 2026.

Transaction Breakdown

• Security: Common Stock
• Action: Open-market sale (Transaction Code S)
• Shares Disposed: 1,132 shares
• Execution Price: $869.43 per share
• Total Gross Proceeds: $984,194.76
• Post-Transaction Holdings:
  • Direct: 10,871 shares
  • Indirect (401(k) Plan): 219 shares

Rule 10b5-1 Plan Context

According to the filing footnotes, this transaction was conducted pursuant to a pre-arranged trading plan intended to satisfy Rule 10b5-1(c), adopted on February 17, 2026.

Market & Trading Significance

• Impact: Low
• Rationale: The transaction represents a routine disposition executed under a pre-established Rule 10b5-1 trading plan adopted over eight months prior. McCourt sold approximately 9.4% of her direct equity holdings, retaining 10,871 direct shares. Scheduled 10b5-1 sales by executive officers are standard corporate practice for liquidity and diversification and rarely signal a change in business fundamentals.